Megestrol acetate

Generic Name: Megestrol acetate

Brand Names: Megace

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₂O_₄

CAS Number: 595-33-5

Unique Ingredient Identifier: TJ2M0FR8ES

Background: 17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.

Indication: For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.

Associated Conditions: Anorexia, Cachexia, Inoperable Carcinoma of Breast, Inoperable Endometrial Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Endometrial Carcinoma, Significant, Unexplained Weight Loss, Metastatic Endometrial carcinoma

Associated Therapies: Palliative Treatment

Clinical Trials

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Phase 1

Recruiting

Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Metastatic Endometrial Endometrioid Adenocarcinoma
Recurrent Endometrial Endometrioid Adenocarcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ipatasertib
Procedure: Magnetic Resonance Imaging
Drug: Megestrol Acetate

First Posted Date: 2022-09-14

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT05538897

Locations: 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States

and more 148 locations

A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore

Phase 2

Conditions: Endometrial Hyperplasia
Fertility Issues
Disease Regression
Treatment Side Effects

Interventions: Drug: Mirena
Drug: Megace

First Posted Date: 2022-08-08

Last Posted Date: 2022-08-08

Lead Sponsor: KK Women's and Children's Hospital

Target Recruit Count: 60

Registration Number: NCT05492487

Locations: 🇸🇬
Singapore General Hospital, Singapore, Singapore
🇸🇬
National University Hospital, Singapore, Singapore
🇸🇬
KK Women's and Children's Hospital, Singapore, Singapore

Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients.

Phase 2

Conditions: Anorexia

Interventions: Drug: Megestrol Acetate
Drug: Mirtazapine

First Posted Date: 2022-05-18

Last Posted Date: 2022-05-18

Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Target Recruit Count: 80

Registration Number: NCT05380479

Locations: 🇧🇩
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer

Phase 1

Terminated

Conditions: Endometrial Cancer

Interventions: Drug: Megestrol Acetate

First Posted Date: 2022-04-18

Last Posted Date: 2023-11-03

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 5

Registration Number: NCT05332483

Locations: 🇨🇦
Sunnybrook Health Sciences, Toronto, Ontario, Canada

Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features

Phase 2

Recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Olaparib
Other: Observation
Radiation: Pelvic external beam radiotherapy
Drug: Durvalumab
Drug: Medroxyprogesterone Acetate
Radiation: Vaginal brachytherapy
Drug: Chemotherapy
Drug: Megestrol Acetate

First Posted Date: 2022-02-24

Last Posted Date: 2024-11-28

Lead Sponsor: Leiden University Medical Center

Target Recruit Count: 1615

Registration Number: NCT05255653

Locations: 🇨🇦
The POLEmut-BLUE trial: Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
🇳🇱
Medisch Spectrum Twente, Enschede, Netherlands
🇳🇱
The MMRd-GREEN trial: Leiden University Medical Center, Leiden, Netherlands

and more 11 locations

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Phase 3

Recruiting

Conditions: Anorexia
Hematopoietic and Lymphoid Cell Neoplasm
Advanced Malignant Solid Neoplasm

Interventions: Drug: Olanzapine
Drug: Megestrol Acetate
Other: Questionnaire Administration

First Posted Date: 2021-06-25

Last Posted Date: 2025-04-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 360

Registration Number: NCT04939090

Locations: 🇺🇸
Illinois CancerCare - Washington, Washington, Illinois, United States
🇺🇸
Rush-Copley Healthcare Center, Yorkville, Illinois, United States
🇺🇸
Northwest Cancer Center - Main Campus, Crown Point, Indiana, United States

and more 269 locations

Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia

Phase 3

Withdrawn

Conditions: Endometrial Hyperplasia

Interventions: Drug: Levonorgestrel Drug Implant
Drug: Megestrol Acetate

First Posted Date: 2021-05-21

Last Posted Date: 2023-07-05

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT04897217

Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia

Phase 2

Terminated

Conditions: Atypical Endometrial Hyperplasia

Interventions: Drug: Metformin plus Megestrol acetate
Drug: Megestrol Acetate

First Posted Date: 2020-10-29

Last Posted Date: 2022-04-05

Lead Sponsor: Fudan University

Target Recruit Count: 12

Registration Number: NCT04607252

Locations: 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, Shanghai, China

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer

Phase 2

Recruiting

Conditions: Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Endometrial Carcinoma

Interventions: Procedure: Biopsy Procedure
Drug: Megestrol Acetate
Drug: Extended Release Metformin Hydrochloride
Other: Questionnaire Administration

First Posted Date: 2020-10-06

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT04576104

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 5 locations

Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia

Phase 2

Completed

Conditions: Atypical Endometrial Hyperplasia

Interventions: Drug: Megestrol Acetate
Drug: Rosuvastatin

First Posted Date: 2020-07-29

Last Posted Date: 2024-01-29

Lead Sponsor: Fudan University

Target Recruit Count: 36

Registration Number: NCT04491682

Locations: 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy